TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling PathwayBrian Tomkowicz, Timothy J. McCabe, Nina Chi-Sabins et al.|PLoS ONE|2015Cited by 80
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s DiseaseMatthieu Allez, Taku Kobayashi, Bruce E. Sands et al.|Journal of Crohn s and Colitis|2023Cited by 11